HEMOSTEMIX ANNOUNCES ACP-01 TREATMENT-PURCHASE AVAILABLE WITH SOCIAL MEDIA CAMPAIGN UNDERWAY November 25, 2024 Read More »
HEMOSTEMIX ANNOUNCES THE FIRST TRANCHE CLOSING OF $1.8M OF ITS RECENTLY ANNOUNCED PRIVATE PLACEMENT October 31, 2024 Read More »
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01 August 1, 2024 Read More »
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments June 3, 2024 Read More »
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences February 6, 2024 Read More »
